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T h e  third c o m p o n e n t  of  complemen t  (C) ~ has a central  role in the activation 
of  both  the classical and al ternat ive pathways. C3 also has a variety o f  di f ferent  
functions that  are  expressed e i ther  a f ter  C3 activation or  dur ing  the normal  
b reakdown o f  the molecule.  These  functions of  C3 are  dependen t  upon the 
exposure  within C3 o f  binding sites for  o ther  se rum proteins  or  for  m e m b r a n e  
C3 receptors .  None  o f  these binding sites is available in native C3 (1, 2), and  
each type of  binding site is exposed  only dur ing  C3 activation and subsequent  
f ragmenta t ion .  T h e  s t ructure  and  funct ion o f  the di f ferent  C3 f ragments  and 
the mechanism o f  their  genera t ion  has been  a subject o f  intense research af ter  
initial repor ts  that  inactivated C3b (iC3b) expressed functions that  were distinct 
f rom those of  C3b (3, 4). Recent  studies have now demons t ra t ed  that  factor  I is 
the p r imary  enzyme responsible for  the normal  physiologic b reakdown of  C3b 
(5-7).  T h e  key to defining the pathway of  I cleavage of  C3b was the demons t ra -  
tion that  two different  cofactors are  requi red  for  l cleavage of  C3b and iC3b (6, 
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7). H is the cofactor  for  I cleavage o f  fluid-phase C3b (8, 9), whereas e ry throcyte  
(E) membrane  CRj is the cofactor  for  I cleavage o f  fixed iC3b into fixed C3d,g 
and fluid-phase C3c (6, 7). Even though CR1 may also serve as cofactor  for  I 
cleavage o f  fluid C3b (10), CR~ probably can not  replace H as the control  protein 
o f  the alternative pathway, as patients with inheri ted H deficiency (11) have 
unregula ted  C3 activation resembling patients with I deficiency (12). 
In the present  investigation, the C3 fragments  resulting f rom activation and 
breakdown by I and trypsin were examined  for  binding sites for  six different  
C3-1igands: factors B and H, CRy, CRy, CR3, and conglutinin (K). Evidence was 
obtained for  at least four  distinct binding sites in the C3 fragments  for  these six 
C3 ligands. 
Mate r i a l s  a n d  M e t h o d s  
Buffers. Assays were performed in either isotonic or low ionic strength buffers con- 
taining either divalent cations, EDTA, or EGTA. Isotonic buffers included: Hanks 
balanced salt solution (HBSS) containing 1% BSA and either 0.6 mM calcium and 0.9 
mM magnesium or 20 mM EDTA; and gelatin veronal buffer (GVB) containing either 
0.15 mM calcium and 0.5 mM magnesium or 0.15 mM nickel. The low ionic strength 
buffers used were: dextrose gelatin veronal buffer (DGVB, 4 mS at 22°C) containing 
either 0.15 mM calcium and 0.5 mM magnesium or 0.15 mM nickel; 3.5 mM veronal 
buffer containing 10 mM sodium chloride, 1% BSA, 3.5% dextrose, 0.2% sodium azide, 
and 2 mM each of calcium chloride and magnesium chloride (BDVA, pH 7.2 and 4 mS 
at 22°C); and calcium-magnesium-free BDVA with 20 mM EDTA (BDVEA, pH 7.2 and 
6 mS at 22°C). 
Leukocvtes and Ervthrocvtes (E). Blood from normal volunteers was drawn into acid 
citrate dextrose anticoagulant. After sedimentation of erythrocytes with dextran, mono- 
nuclear cells and neutrophils were separated by centrifugation on a two-step (d = 1.08 
and 1.105) density gradient of FicolI-Hypaque as previously described (I 3). Erythrocytes, 
taken from the dextran-sedimented fraction, and Raji lymphoblasts, cultured in RPMI 
1640 with 10% heat-inactivated fetal calf serum, were each washed three times in 
phosphate-buffered saline (PBS) before assay of C receptors. Each cell type was suspended 
at 4 × 106/ml in EDTA/HBSS/BSA, and maintained at room temperature until exam- 
ined for C receptors. Soybean trypsin inhibitor (Sigma Chemical Co, St Louis, MO) at 1 
mg/ml was added to all neutrophil preparations to inhibit elastase activity (13). Where 
indicated, portions of each cell type were resuspended before C receptor assay at 4 × 
106/ml in either HBSS/BSA, BDVA, or BDVEA. 
C Components, To,psi,, and Serum Reagents. C3, B, D, H, and I were isolated as 
previously described (6, 14). Trypsin was obtained from Sigma Chemical Co. Isotonic and 
low ionic strength (4 mS at 22°C) heat-inactivated serum reagents were prepared as 
before (6). 
Purificatio, of C3 Fragments. C3b, iC3b, C3c, C3d,g, and C3d were prepared on 
Activated Thiol Sepharose (ATS, Pharmacia Fine Chemicals, Piscataway, NJ) and eluted 
with 10 mM cysteine, pH 7.0 as previously described (6). ATS-iC3b was prepared by H 
and I treatment of ATS-C3b in isotonic salt buffer, and contained no trace of C3b or 
C3d,g on SDS-PAGE. ATS-C3d,g, prepared by H and I treatment of ATS-C3b at low 
ionic strength (1.4 mS), contained ~10% iC3b (6). To remove iC3b from one C3d,g 
preparation, the C3d,g was absorbed with agarose coupled to monoclonal anti-C3c (clone 
4) (15). Two C3c preparations were used, one generated by elastase treatment of ATS- 
C3b, and the other by H and I treatment of ATS-C3b in 1.4 mS buffer (6). 
Preparation of C3-Coated Fluorescent Microspheres. Fluorescent microspheres (Covas- 
pheres, Covalent Technology Corp, Ann Arbor, MI) were coated with iC3b, C3d,g, and 
C3c as previously described (13). Control BSA-coated microspheres were always prepared 
in parallel. 
Formatio, of Sheep Eo,throcvte-C3 Complexes (EC3) and Quantitation of The Different Fixed 
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C3 Fragme~ts With veSI-Labeled Monoclonal Antibodies Specific For C3c, C3g, and C3d. EC3b 
was prepared by two cycles of  C3 addition, first with trypsin, and then with a bound 
nickel-stabilized C3-convertase formed with B and D (6). EC3bi was prepared by treatment 
of  EC3b for 15 min at 37°C with isotonic heat-inactivated serum, 1.0 ml per 1 x 109 
EC3b (6). EC3d,g was prepared by treatment of  EC3b for 60 min at 37°C with 4 mS 
heat-inactivated serum, 1.0 ml per 1 x 109 EC3b (6). EC3d was prepared from EC3bi or 
EC3d,g by incubation for 30 min at 37°C at 1 x 109/ml in PBS containing 10 ~g/ml  of  
trypsin (6). EC3 were prepared with different amounts of  C3 and the amount and type of  
bound C3 fragments were quantitated by assay for uptake of  v"~I-labeled monoclonal 
antibodies specific for C3c, C3g, and C3d (6). One anti-C3c IgG (kindly donated by Dr. 
Charles Parker, Duke University, Durham, NC) was purified from ascites fluid obtained 
from Bethesda Research Laboratories (Gaithersburg, MD) by column chromatography 
on DEAE cellulose. A second anti-C3c IgG, clone 4, (15) was isolated from ascites fluid 
(made pH 5 with acetic acid) by precipitation with 5% caprylic acid (Sigma Chemical Co.) 
followed by precipitation of  the caprylic acid supernatant with 50% saturated ammonium 
sulphate. Clone 9 anti-C3g (15) and clone 3 anti-C3d (15) were isolated in a similar way. 
Each anti-C3 was iodinated to a specific activity of  0.7-2.5 uCi/t~g IgG using Iodogen 
(Pierce Chemical Co., Rockford, IL) (16). 
In the first step of  C3 addition with trypsin forming EC3bn, the amount of  C3 and 
trypsin (6) were adjusted for maximum C3b fixation without further trypsin cleavage of  
the bound C3b. Any cleavage of  fixed C3b on the EC3bT was detected with ~25I-anti-C3g, 
that bound only to fixed iC3b and to fixed C3d,g and not to fixed C3b (6, 17). The 
analysis of  a typical preparation of  EC3 is given in Table I. Conversion of  EC3b to EC3bi 
o 1 2 ~  required 5 min at 37 C, and was determined to be complete when the uptake of  I-anti-  
125 1 2 5  C3g was equivalent to the uptake of  ' I-anti-C3c and '" I-anti-C3d. Incomplete conversion 
to iC3b was indicated if the uptake of  ~25I-anti-C3g was less than the uptake of  ~25I-anti- 
C3c and ~25I-anti-C3d, whereas over-cleavage of  iC3b to C3d,g was indicated when the 
uptake of  ~251-anti-C3c was less than the uptake of  J2'~I-anti-C3g and ~25I-anti-C3d. These 
conclusions derived with monoclonal antibodies were initially confirmed by SDS-PAGE 
and autoradiography of  EC3 prepared with J25I-labeled C3 (6). EC3d,g always contained 
5% factor I-resistant C3b and iC3b, as indicated both by uptake of  v~SI-anti-C3c (Table I) 
and by SDS-PAGE autoradiography (6). EC3d contained ~ 3 %  contaminating C3b, but 
no detectable iC3b. This was indicated both by the uptake of  ~25I-anti-C3c in the absence 
of  significant uptake of  J25I-anti-C3g (Table I) and by SDS-PAGE autoradiography of  
EC3d prepared with v25I-labeled C3. (6). 
Anti-CRy, Anti-H, and Anti-Mac-1. Rabbits were immunized with purified CRj (10, 18) 
or H (14), and the F(ab').~ fragments of  the IgG antibodies were isolated (18). Analysis of  
TABLE I 
Detection A~ld Qua~ttitatiolt Of Different C3 Fragments on EC3 With 
12r'l-Labeled Monoclo~ml Antibodies Specific for C3c, C3g, and C3d 
EC3 type 
Molecules 1251-anti-C3 bound per EC3 
Anti-C3c Anti-C3g Anti-C3d 
EC3bT* 5.7 x 103 1.3 x 102 5.4 × l0 s 
EC3b* 3.3 x 104 2.1 x 10 '~ 3.5 x 104 
EC3bi § 2.8 x 104 2.7 x 104 2.8 × 104 
EC3d,g~ 8.1 × 102 2.5 x 104 2.6 X 104 
EC3d ~ 7.1 X 10 ~ 2.4 × 10 j 2.3 X 104 
* EC3b~-: prepared by trypsin activation of 2 mg of C3 in the presence of 
1 x 10~° sheep E. 
* EC3b: prepared by addition of 100/~g C3 per 1 X 109 EC3bT,Bb,Ni ++ 
(see Materials and Methods). 
§ EC3bi, EC3d,g and EC3d were prepared from EC3b (see Materials and 
Methods). 
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the anti-H by immunodiffusion and immunoelectrophoresis demonstrated a single precip- 
itin line of identity between purified H and human serum. In addition, the anti-H did not 
contain anti-C3 detectable by assay for agglutination of EC3b nor anti-CR~ detectable by 
assay for inhibition of human E rosette formation with EC3b. Tissue culture supernatant 
containing 100 #g/ml of anti-Mac-1 antibody (19) was kindly provided by Dr. T. Springer 
(Sidney Farber Cancer Institute, Boston, MA). 
Soluble C3d-Sheep E Membrane Complexes (C3d-OR). The membranes of 6 × 10 "q EC3d 
bearing 7.1 × 104 C3d per E, and only 3.6 × 103 C3b and 7.1 × 101 iC3b per E, were 
produced by lysis of the EC3d in 5 mM phosphate buffer, and then were solubilized with 
0.25% Nonidet P40 as described by Fearon et al. (20) for C3b-OR. After removal of 
detergent with Bio-Beads SM-2 (Bio-Rad Laboratories, Richmond, CA) the C3d-OR were 
concentrated to 1.2 ml, dialyzed against BDVA, and stored at 4°C. 
Assal's For Factor B Bindil~g To C3. Purified B was examined for binding to C3b and 
iC3b tl~at were covalently attached to ATS or sheep E. 1-cm x 15-cm columns containing 
either ATS-C3b or ATS-iC3b (3.4 mg C3b or iC3b/ml ATS) (6) were equilibrated with 
3.5 mM veronal buffer, pH 7.2 containing either 0.5 mM magnesium chloride or 0.15 
mM nickelous chloride (-~ 1 mS at 22°C). Binding of 5.0 mg of B passed through these 
two columns was assessed by measuring B hemolytic activity in 1-ml fractions eluted at 20 
ml /h  at 4°C. The B contained 10% contamination with hemopexin that was monitored 
in column fractions by Ouchterlony assay. B titrations were performed with EC3b (1 x 
10S/ml) in DGVB containing 0.15 mM nickelous chloride, (DGVB-Ni). 25/zl dilutions of 
B in DGVB-Ni were mixed with 25 ul of  D (200 ng/ml) and 25/zl of EC3b in V-bottom 
microtiter plates and incubated with agitation for 3 min at 37°C. Next, 25/~1 of 80 mM 
EDTA, pH 7.2 and 25 ~1 of guinea pig C diluted 1:15 in 40 mM EDTA-GVB were added 
in succession, and incubation continued with agitation for 45 rain at 37°C. To assess B 
binding to EC3bi, this assay was carried out with EC3bi instead of with EC3b. 
Assay for H Binding to EC3b and EC3bi. H (2 mg) was labeled with 0.5 mCi 12~I using 
Iodogen (16), and had a specific activity of 0.05 t~Ci/gg. Increasing volumes of the [125I]- 
H (750 ug/ml  in PBS) were added to duplicate 10-mm × 75-mm plastic tubes containing 
1 × l0 s sheep E, EC3b, or EC3bi in either GVB or DGVB to give a total volume of 200 
~zl, After incubation for 30 min at 30°C, 100 ~1 (5 x 107 cells) was layered onto 1.0 ml of 
a 7:3 mixture of n-butyl phthalate and dinonyl phthalate (Sigma Chemical Co.) in a 1.5- 
ml tube and centrifuged for 45 s at 8,000 g. The supernatant containing the free [I~sI]-H 
was then aspirated and the amount of EC3-bound [12"~I]-H was determined by cutting off 
the bottom of the tube just above the pellet and counting it in a gamma counter (23). 
The nonspecific uptake of [r"~I]-H by E was subtracted from the total [12"~I]-H uptake 
observed with EC3 to determine the specific uptake of ['2'~I]-H. The concentration of free 
unbound [v~sI]-H was calculated by subtraction of the specifically bound [125I]-H concen- 
tration from the total [v~~I]-H concentration in the assay mixture. The H-binding affinity 
was determined from the slopes of Scatchard plots derived by plotting the ratio of bound/  
free H concentrations versus the concentration of bound H (24). 
Assay of A~ti-H and anti-CR~ for Inhibition of 4 mS Serum-mediated C3c Release from 
EC3bi. 1.0-ml volumes of low ionic strength heat-inactivated serum (6) were mixed with 
250/zl of either PBS, F(ab')e anti-H (18.1 mg/ml),  F(ab'),~ anti-CR1 (1.65 mg/m[), or a 
mixture containing F(ab')z anti-H and F(ab')2 anti-CR1 (18.1 mg/ml  and 1.65 mg/ml  
respectively). The amount of  anti-CR~ used was shown to be sufficient to block the EC3b 
rosetting ability of 4 × 109 human E. After 1 h at room temperature, the antibody- and 
PBS-treated samples were centrifuged at 10,000 g for 30 min to remove immune 
precipitates. Each of the H- and /or  CRy-depleted serum reagents were then added to 
pellets of 1 x 109 EC3bi (2. I x 104 iC3b per E), and following resuspension of the EC3bi, 
the mixtures were incubated for 2 h at 37 °C. After three washes with BDVEA, the EC3bi 
were analyzed for conversion to EC3d,g by tests for the uptake of ~SI-labeled anti-C3c 
and anti-C3g (6). To  distinguish nonspecific shedding of uncleaved iC3b molecules from 
the EC3bi, an additional 1 × 10 "° EC3bi were incubated in 1.0 ml of DGVB for 2 h at 
37 °C. I-specific C3c release was determined from this control (6). 
C Receptor Assays. C receptors were assayed by rosette formation with EC3 or C3-ms 
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(13). The buffer used for rosette assays is listed in Tables I -V.  With some recently 
purchased lots of  microspheres, nonspecific binding of  BSA-ms was so high that these lots 
of  microspheres could not be used for preparation of  C3-ms. 
Assays For C Receptor Specificity,. C receptor specificity was determined by treatment of  
C receptor cells with either anti-C-receptor antibody, C3 fragments, or C3d-OR before 
assay of  C-receptors (13). The F(ab')~-anti-CRl was 8.2 mg/ml  in PBS and 5 #1 (41 ug) 
was sufficient to inhibit CR~ activity completely on 4 x 10 ~ monocytes or neutrophils. 
Anti-Mac-1 was used to inhibit CRs activity (21). Monocytes and neutrophils (4 x 10 "~) 
were treated with 10 #1 to 20 #1 of  anti-Mac-1 tissue culture supernatant and then washed 
once before assay of  C receptors. The  concentrations of  C3 fragments used for inhibition 
are listed in Table II. 50 #1 of  C3d-OR was required to produce 50% inhibition of  EC3d 
rosette formation with Raji cells, and the same amount of  C3d-OR was used in experiments 
with monocytes and neutrophils. 
In experiments that examined the divalent cation requirements for EC3bi binding to 
CRs and K, the EC3bi and monocytes (anti-CRj-treated) were first washed with 20 mM 
E D T A / H B S S / B S A  and then washed twice and resuspended in HBSS/BSA containing 
either 2 mM calcium chloride, a mixture of  2 mM EGTA and 2 mM magnesium chloride, 
or a mixture of  2 mM calcium chloride and 2 mM magnesium chloride. 
N-acetyl-n-glucosamine (NADG) was purchased from BDH chemicals Ltd. (Poole, 
England) and various amounts were added to BDVA. After incubation of  both EC3bi and 
monocytes (anti-CRy-treated) in the N A D G / B D V A  for 15 min at 22°C, the EC3bi were 
mixed with the monocytes and analyzed for rosette formation. 
Put,cation and Assay of K. K was isolated from bovine serum by EDTA elution from 
yeast cell walls (22). K was titrated in U-bottom microtiter plates for conglutination of  
EC3bi suspended at 1 x 10~/ml in GVB containing either 2 mM calcium chloride, 2 mM 
each of  EGTA and magnesium chloride, or 2 mM each of  calcium chloride and magnesium 
chloride. Conglutination was allowed to develop for 2 h at 4°C before visual estimation 
of  the 50% endpoint. 
Results 
Binding of B to C3b but Not to iC3b. Previous studies have demonstrated that 
under physiologic conditions B binds to C3b but not to iC3b, and that binding 
requires magnesium (Mg++). Because the binding of  B to C3b is charge-dependent 
(23) and enhanced by substitution of  nickel (Ni ++) for Mg ++ (25), studies were 
undertaken to determine if a binding site for B could be detected in iC3b using 
a low ionic strength buffer containing Ni ++. First, B was passed through two 
columns containing either ATS-C3b or ATS-iC3b in 1.0 mS buffer with Mg ++. 
All B was bound to the ATS-C3b and subsequently eluted with 10 mM EDTA 
in veronal-buffered saline. By contrast, B was not bound to ATS-iC3b in either 
Mg ++ or Ni ++, and eluted in the same fractions as did hemopexin. 
When B was assayed for binding to EC3b (4.5 × 104 C3b per E) by hemolytic 
assay in DGVB-Ni, 50% lysis was obtained with as little as 0.5 #g /ml  of  B (7.5 
molecules B/molecule fixed C3b). However, when EC3bi (5.7 × 104 iC3b per 
E) were substituted for EC3b, no B-mediated hemolysis was detectable with B 
serial dilutions starting at 1.0 mg /ml  (1.2 × 104 molecules B/molecule fixed 
iCSb). 
Demonstration of a Binding Site for H and CRI in C3b, iC3b, and C3c. The  
binding of  [~25I]-H to EC3b and EC3bi was examined in both low (4 mS) and 
isotonic salt buffers (Fig. 1). H binding to EC3b was readily detectable in GVB, 
whereas H binding to EC3bi was only observed in DGVB.  The  calculated affinity 
o f  H for EC3b was 5 x 106 M -1 in GVB and 1.8 x 107 M -I in DGVB, and for 
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FIGURE l. Binding of 12~I-labeled factor H to EC3b and EC3bi in isotonic versus low ionic 
strength buffer. Different amounts of []2~I]-H were added to either E, EC3b, or EC3bi in 
either GVB (15 mS at 22°C) or DGVB (4 mS at 22°C), and the amount of specifically bound 
[125I]-H was determined by subtraction of the nonspecific [J25I]-H binding to E from the total 
binding of [J25I]-H to EC3b or EC3bi. The  specific uptake of [1251]-H in molecules per EC3b 
" 125 or EC3bi was plotted versus the initial unbound concentrauon of [ I]-H. The  EC3b were 
shown to bear 3.34 x 104 C3b molecules per cell by assay for uptake of ~25I-monoclonal anti- 
4 C3c, whereas the EC3bi were shown to bear 1.79 X 10 iC3b molecules per cell by assays for 
uptake of 12"~I-anti-C3c and 12~I-anti-C3g (see Materials and Methods). 
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EC3bi in DGVB the affinity was 4 x 10 6 M -~. The calculated number of H 
binding sites on EC3b and EC3bi was approximately the same as the number of 
bound C3b and iC3b molecules respectively as measured by the uptake of  l~sI- 
monoclonal anti-C3c. 
Because low ionic strength serum, but not isotonic serum, converted EC3bi to 
EC3d,g (6), it had been previously hypothesized that the H in low salt serum 
could serve as the I cofactor only because the low salt permitted H binding to 
EC3bi. To confirm this function of serum H, low ionic strength serum was 
treated with either anti-H, anti-CRy, a mixture of  the two antibodies, or PBS, 
and then examined for its ability to convert EC3bi to EC3d,g. Cleavage of EC3bi 
to EC3d,g was monitored by measuring the uptake of ]25I-monoclonal antibodies 
specific for C3c and C3g (6). As previously reported, C3c antigens were rapidly 
lost from EC3bi treated with 4 mS serum, whereas C3g antigens were retained, 
indicating conversion to EC3d,g. Previous addition to the 4 mS serum of anti- 
H, but not anti-CR] or PBS, inhibited C3c release by 85%, and a mixture of  
anti-H and anti-CR] inhibited C3c release by 94%. 
The binding of  iC3b and C3c to CR~ was demonstrated with iC3b- and C3c- 
coated fluorescent microspberes (Table II) and with EC3bi (Table III). H binding 
to C3c was not examined. All rosette assays with C3-ms were performed in buffer 
containing EDTA that prevented the binding of  iC3b to CR3. Both iC3b-ms and 
C3c-ms were inhibited completely from binding to CR]-bearing cells (erythro- 
cytes, monocytes, neutrophils) by either anti-CRy, or fluid-phase C3b, iC3b, or 
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TABLE II 
Spec~city Of Rosette Formation By Microspheres Coated With iC3b, C3d,g and C3c 
Cell type 
C3 fragment Rosette formation in the presence of 
011 micro- 
spheres Buffer* aCRl* C3b § iC3b C3c C3d,g C3d-OR 
Erythrocytes iC3b 75 0 0 0 11 73 69 
C3c 72 0 0 0 14 70 72 
M onocytes iC3b 96 0 6 0 21 97 92 
C3d,g 91 84 86 38 88 23 31 
C3c 80 0 0 0 12 76 77 
Raji cells iC3b 98 99 99 37 99 0 0 
C3d,g 99 99 99 51 99 3 0 
C3c 0 ND ! ND ND ND ND ND 
* Buffer: BDVEA. 
* aCRI: F(ab').2-anti-CR~, 41 #g/4  × 10 "~ erythrocytes or leukocytes. 
§ C3 fragment concentration: C3b, 500 ug/ml; iC3b, 400 ug/ml; C3c, 1.25 mg/ml; C3d,g, 350 ug /  
ml. 
I ND, not done. 
C3c (Table II). With Raji cells that express C R  2 (26) and lack CR1 entirely (14, 
27, 28), iC3b-ms binding was not inhibited by anti-CRy, and C3c-ms rosettes 
were not observed. The results obtained with EC3bi were similar to those 
obtained with iC3b-ms; i.e. rosette formation in EDTA buffers was inhibited 
completely by anti-CRl (Table III). CRl-dependent rosette formation with EC3bi 
required more C3 per cell than did EC3b rosette formation. With EC3b, 
erythrocyte rosette formation (immune adherence) was near maximum levels 
with 4 x 103 C3b per E (29, 30). However, with EC3bi, immune adherence was 
undetectable with 1.4 x 104 iC3b per E in isotonic salt buffer, and maximum 
levels of immune adherence required 3.5 x 104 iC3b per E and low-salt buffer 
(Table III). Even though EC3bi contained 5% C3b contamination, this C3b did 
not explain the CR~ activity of EC3bi, as treatment of CRvpositive EC3bi with 
10 •g/ml of trypsin formed EC3d that still contained 3-5% contaminating C3b 
(Table I), but totally abolished binding to CRl-bearing cells (E, monocytes, and 
neutrophils). When EC3bi rosette formation was assayed with phagocytes in 
buffers containing calcium and magnesium, EC3bi bound to both CR~ and CRs, 
so that little inhibition of  rosette formation was produced by anti-CR~ (Table 
III). By contrast, anti-CR~ produced complete inhibition of human erythrocyte 
rosettes with EC3bi in calcium-magnesium buffer (BDVA), indicating that EC3bi 
did not bind to erythrocyte CRs. With EC3bi bearing small amounts of iC3b (< 
1.4 × 104 iC3b per E), rosette formation with monocytes and neutrophils in 
isotonic HBSS/BSA was primarily CRy-dependent and selectively inhibited by 
anti-Mac- 1 (Table I I I). As reported by Beller et al. (21), anti-Mac- 1 had no effect 
on CR1 activity measured either with EC3b (data not shown) or with EC3bi in 
EDTA (Table III). 
Location of the CR2-Bindi,g Site in the d Region of iC3b, C3d,g, a~d C3d. Previous 
studies of CRz had demonstrated a specificity for both iC3b and C3d, and a 
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TABLE III 
Differences in the C Receptor Specificity of EC3bi Rosette Formation Dependent Upon Divalent 
Cations, Ionic Strength, and Amount of iC3b 
EC3bi Rosette Formation 
C3bi tools HBSS/ EDTA/ BDVEA 
Cell type Antibody treat- per EC3bi BSA (Ca, HBSS/ BDVA (Ca, (EDTA 6 





- -  14 0 0 21 10 
- -  37  15 5 3 9  2 2  
- -  6 5  2 2  8 6 0  3 2  
Anti-CR~ 65 0 0 0 0 
- -  7 . 9  5 9  0 8 6  0 
- -  14 8 6  8 9 5  18 
Anti-CR~ 14 74 0 95 0 
Mac-1 14 5 6 20 13 
- -  37  9 7  4 3  9 5  8 2  
- -  6 5  9 6  77  9 7  8 5  
Anti-CRi 65 85 0 94 0 
Mac-1 65 75 74 92 81 
- -  14 9 6  2 1 0 0  11 
Anti-CR1 14 79 0 100 0 
Mac-1 14 4 3 13 9 
- -  37  9 9  7 8  1 0 0  8 4  
- -  6 5  9 9  9 7  1 0 0  8 8  
Anti-CR1 65 92 0 100 0 
Mac-I 65 95 93 100 86 
complete  absence o f  reactivity with C3b (13, 14, 26). Because earlier preparat ions 
o f  EC3bi and EC3d probably contained variable amounts  o fC3d ,g ,  a C3 f ragment  
that was previously unrecognized,  f luorescent microspheres were coated with 
iC3b and C3d,g that were shown to be pure  by SDS-PAGE, and then examined 
for  binding to different  cell types (Table  II). In addition, the specificity of  rosette 
format ion with EC3bi (Table III) and EC3d,g (Table IV) was characterized.  
Both iC3b-ms and C3d,g-ms rosettes with CR2-bearing Raji cells were inhibited 
by fluid-phase iC3b, C3d,g, and C3d-OR (Table II). Similar results were obtained 
with EC3bi and EC3d,g (data not  shown). Fur the rmore ,  C3d-ms binding to Raji 
cells was blocked by fluid phase iC3b and C3d,g (data not  shown). 
Monocytes and neutrophils  that had been thought  to lack CR~ because o f  
absence o f  roset t ing ability with EC3d and C3d-ms (13), bound  C3d,g-ms (Table 
II) and EC3d,g containing more  than 5 x 104 C3d,g per  E (Table IV). C3d,g- 
ms rosettes with phagocytic cells were not inhibited significantly by E D T A  a n d /  
or  anti-CR, (Table  II), indicating that binding was probably not  due  to small 
amounts  o f  contaminat ing C3b or iC3b binding to CR~ and CRs. Both C3d,g-ms 
and EC3d,g rosettes with phagocytes were inhibited by C3d-OR (Tables II and 
IV), suggesting the presence o f  a phagocyte  CRz-like C3d receptor .  However ,  
because the EC3d,g was known to contain small amounts  o f  contaminat ing C3b 
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TABLE IV 
Spec~citl' of EC3d,g Rosette Formation 
Cell type 
EC3d,g* Rosette Formation in the presence of 
Buffer* Anti-CR~ C3d-OR Anti-CRl + 
C3d-OR 
Erythroyctes 0 ND ~ ND ND 
Monocytes 87 74 12 3 
Neutrophils 95 76 48 21 
Raji cells 99 99 46 48 
* EC3d,g: 6.9 x 104 molecules of C3d,g per E, with C3b/ iC3b  contamination of 
1.5 x 103 molecules per E determined by uptake of J2~I-anti-C3c. 
* Buffer: BDVA. 
ND, not done. 
and iC3b, and because the C3d-OR contained 5% C3b-OR, a potent inhibitor of 
CR1 (20), inhibition studies with anti-CR1 were performed to determine if EC3d,g 
bound to CR1 (Table IV). Amounts of anti-CR~ sufficient to inhibit completely 
EC3b rosette formation, did produce ,~ 18% inhibition of monocyte and neutro- 
phil rosette formation with EC3d,g. Even though this was much less than the 
72% inhibition (average) produced by C3d-OR, a mixture of anti-CR1 and C3d- 
OR consistently produced more inhibition than did C3d-OR alone, suggesting 
that some phagocyte rosettes with EC3d,g were due to contaminating C3b or 
iC3b binding to CR1. Since the EC3d from which the C3d-OR were prepared 
contained virtually no iC3b detectable with 125I-anti-C3g, it appears unlikely that 
the C3d-OR contained iC3b-OR that inhibited EC3d,g from binding to CR3. 
Furthermore, despite the finding that monocyte and neutrophii rosettes with 
EC3d,g were not observed in the presence of EDTA (data not shown), C3d,g- 
ms did bind to monocytes (Table II) and neutrophils (not shown) in the presence 
of EDTA and anti-CRl. 
The observation that monocytes and neutrophils expressed C3d-specific recep- 
tors that bound EC3d,g and C3d,g-ms, but not EC3d or C3d-ms (13), suggested 
the possibility that phagocytic cells might express low numbers of CR2,  and that 
t h e s e  CR2 were detectable only with EC3d,g and C3d,g-ms because C3d,g had a 
higher affinity for C R 2  than did C3d. Comparison of EC3d,g and EC3d CR2-  
dependent rosette formation with Raji cells supported this hypothesis (Fig. 2). 
Raji cells bound EC3d,g that contained as few as 700 molecules of C3d,g per E, 
and nearly all cells were rosetted with EC3d,g bearing 2,200 C3d,g per cell. By 
contrast, Raji cells did not form rosettes with EC3d containing 900 C3d per E, 
and maximum rosette formation required "~5,000 C3d per E. 
Because C R 2  had a higher affinity for C3d,g than for C3d, EC3d,g were coated 
with saturating amounts of monoclonal anti-C3g to determine if this blocked the 
CR2-binding site. The observation that this treatment of EC3d,g (700 C3d,g per 
E) did not inhibit Raji cell rosettes, probably indicates that the g region does not 
form part of  the CR2-binding site. 
Demonstratio~ of a Common Binding Site for CR3 and K in iC3b. Because iC3b 
bound to both CR~ and CR3 (Table III), the characteristics of CR~ binding to 
iC3b could only be examined with granulocytes on which the CR~ was blocked 
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FIGURE 2. Raji cell rosette formation with EC3d,g and EC3d prepared with different 
amounts of C3. Different EC3bT were prepared with 1 × 10 ~ E and varying amounts of C3 
(0.5 nag to 3.0 rag), 1~ trypsin (wt/wt), and incubation for 1 min at 37°C. Each different 
EC3bT was divided into two parts that were converted into either EC3d,g or EC3d and then 
analyzed for uptake of ~25I-labeled monoclonal anti-C3c, anti-C3g, and anti-C3d. Rosette 
formation was carried out in BDVEA buffer by incubation for 15 min at 37°C on a tube 
rotator (see Materials and Methods). 
T A B L E  V 
Requirements for Divalent Cations and Carbohydrate in the Binding of EC3bi 
to CRs and Bovine Conglutinin 
EC3bi ro- 
Molecules of iC3b/ settes with EC3bi conglu- 
EC3bi anti-CR1- tination titre 
treated mon- (K)* 
ocytes (CRy) 
BDVA 
+ 3 mM NADG 
+25 mM NADG 
BDVA 
+ 3 mM NADG 
+ 25 mM NADG 
HBSS/BSA* 
+ 20 mM EDTA 
+ 2 mM Mg-EGTA 
+ 2 mM CaCI~ 
+ 2 mM MgCI2 and 
2 mM CaC12 
7.9 × 10 3 
1.4 × 10 4 












* One preparation of purified K, 100 ~g/ml, was titrated under the different 
conditions listed. 
* HBSS/BSA: Calcium and magnesium-free HBSS with I% BSA. 
with s a t u r a t i n g  a m o u n t s  o f  an t i -CRl .  CR3 r e s e m b l e d  K in tha t  CR3 b o u n d  only  
to iC3b a n d  did  no t  b i n d  to C3b,  C3c (13, 31), C3d ,g  (Tab le  IV a n d  r e f e r e n c e  
31) or  C3d  (13, 31). In  add i t ion ,  bo th  CR3 a n d  K b i n d i n g  to EC3bi  was i nh i b i t e d  
comple te ly  by E D T A  (Tab le  I I I  a n d  r e f e r e n c e  32). Because K b i n d i n g  to EC3bi  
was k n o w n  to r e q u i r e  bo th  ca lc ium cat ions a n d  c a r b o h y d r a t e  (32), CR~ was 
c o m p a r e d  to K for  these  two character is t ics  (Tab le  V). A m o n g  the  several  sugars  
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known to inhibit K activity, N-acetyl-D-glucosamine (NADG) had been shown to 
be inhibitory at the lowest concentration, 3 mM (33). With EC3bi containing 
amounts of iC3b (7.9 × 103 molecules per E) that were suboptimal for CRy- 
dependent rosette formation and K activity, 3 mM NADG produced little 
inhibition of rosette formation, but completely inhibited K activity. Higher 
amounts of NADG did produce significant inhibition of CR~ activity in a dose- 
dependent manner, with nearly complete inhibition of CR3 obtained with 25 
mM NADG. However, with EC3bi containing greater amounts of iC3b (1.4 × 
104 molecules per E), 25 mM NADG consistently produced an average of only 
32~ inhibition of CR3 activity, while completely blocking conglutination. 
To examine CR~ and K cation requirements, EC3bi and monocytes in E D T A /  
HBSS/BSA were washed into HBSS/BSA containing either magnesium and 
EGTA (to chelate calcium), calcium only, or a mixture of magnesium and 
calcium, and then examined for CR~ and K activity (Table V). Although both 
CR:~ and K activity were restored with calcium, CR~ differed from K in that a 
low level of CR3 activity was detectable in magnesium-EGTA, and calcium and 
magnesimn produced much greater CR3 activity than did calcium alone. In 
another type of test, CR3 also resembled K in that both CR3-dependent neutrophil 
EC3bi rosettes and clumps of conglutinated EC3bi were disrupted by addition 
of EDTA followed by mild agitation. 
Discussion 
The major conclusion of the present study was that C3 contained at least 4 
distinct binding sites for 6 of 11 known C3-1igands. One binding site for factor 
B was present in C3b, but was destroyed completely by factor I cleavage of C3b 
into iC3b. A second binding site for factor H and CR1 was expressed in the c 
region of C3b, and was still detectable, although with reduced affinity, in iC3b 
and C3c. A third binding site for CRe was located in the d region of C3 and was 
exposed only after I cleavage of C3b into iC3b or C3d,g. The data suggested 
that the very anionic g portion of C3d,g might enhance the charge-dependent 
binding affinity of CR2 for C3d. The fourth binding site included a carbohydrate 
moiety of C3 that was exposed only in the iC3b fragment and bound both CR3 
and conglutinin (K). 
C3 has a central role in both the classical and alternative pathways, and has 
more functions than any other single C component. Each function of C3 is 
dependent upon the expression within the molecule of a variety of different 
binding sites, as no enzymatic activity has ever been found in the molecule. After 
C3 activation, the labile binding site is generated in C3b by disruption of an 
internal thiolester bond in the d region (34), and this results in a proportion of 
the C3b molecules becoming bound covalently to nearby carbohydrate or protein 
surfaces. The C3a and C3b fragments and the products of C3b degradation by 
I (iC3b, C3c, and C3d,g) and trypsin (C3d) express binding sites for eleven 
different ligands: C3a receptor, B, properdin, H, C5, I, CRy, CR2, CR3, C4- 
binding protein, and K. Many previous studies that used different techniques 
have demonstrated distinct binding sites for several pairs of these ligands. For 
example, the concurrent binding to C3b of both Bb and properdin (35), or of H 
and I (36), or of H and properdin (36), indicated that each member of the pair 
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must have a distinct binding site. More recently, the finding of  monoclonal anti- 
C3 antibodies that would selectively inhibit either the B, H, or properdin binding 
sites, indicated separate binding sites for each of these ligands (37, 38). 
The loss of hemolytic activity following H and I cleavage of C3b into iC3b has 
been assumed to indicate that I destroyed the B-binding site in C3b. However, 
it remained possible that a low affinity and /o r  hemolytically inactive B-binding 
site might be present in iC3b. To investigate a possible B-binding site in iC3b, 
both low ionic strength and nickel cations, each of  which are known to enhance 
the binding of B to C3b (23, 25), were used with either ATS-iC3b or EC3bi. 
Because no binding of B to iC3b was detected, the B-binding site in C3b is 
probably destroyed totally by the initial two cleavages with I. 
Previous reports of  H and CR1 binding to C3b suggested either a common 
binding site or partially overlapping sites. The binding of  both H and CR~ to 
C3b is enhanced by low salt buffer (18, 23, 39), and both ligands accelerate the 
dissociation of  Bb from C3b,Bb,P and serve as cofactors for I cleavage of C3b 
and iC3b (6, 8, 10). In addition, high concentrations of H competitively inhibit 
CR1 binding to EC3b (40). Even though H binding to EC3bi was not detected 
by past investigators (21), the finding that H could serve as an I cofactor for 
iC3b cleavage into C3c and C3d,g in low salt buffer (6), suggested that a low 
affinity H-binding site might be present in iC3b. Indeed, [125I]-H binding to 
EC3bi was detectable only in 4 mS DGVB and not in 15 mS GVB (Fig. 1). As 
reported by Kazatchkine et al. (23), the H-binding affinity for EC3b was enhanced 
by low-salt buffer from 5 x 106 M -~ in GVB to 1.8 × 107 M -~ in DGVB. The 
H-binding affinity for EC3bi in DGVB (4 x 10 6 M -1) was only slightly less than 
the H affinity for EC3b in isotonic buffer. The numbers of  H-binding sites on 
EC3b and EC3bi were approximately the same as the numbers of C3b and iC3b 
molecules per cell respectively measured with 125I-monoclonal anti-C3. This 
indicated that nearly all iC3b molecules bound H in low salt buffer, and that H- 
binding to EC3bi was not due to the small amount (<5%) of contaminating C3b 
on EC3bi. 
The observed binding of  H to EC3bi in low salt buffer appeared to confirm 
the mechanism by which low ionic strength permitted either purified H or serum 
H to be an I-cofactor for cleavage of fixed iC3b (6). However, because serum 
might contain very low amounts of free CRy, and because the binding of CRI to 
EC3bi was also increased in low salt buffer (Table III), the possibility existed that 
undetected CR~ in low ionic strength serum might be the factor I-cofactor for 
iC3b cleavage. Tests of  low ionic strength serum however, demonstrated that H 
and not CR~ was the primary I-cofactor for cleavage of  fixed iC3b. Treatment 
of 4 mS serum with anti-H, but not anti-CRl, inhibited C3c release from EC3bi 
by 85%. The possibility remains that a low concentration of  free CR~ in isotonic 
serum might serve as an I cofactor for the iC3b cleavage that has been observed 
in serum after C3 activation with cobra factor and incubation for 6-24  h at 37 °C 
(17). 
All previous reports have failed to demonstrate EC3bi binding to CR~ (13, 18, 
21,41).  The data presented in Tables II and III show the two major reasons for 
this. First, fixed iC3b can bind to all three types of  C3 receptors. Second, the 
binding of EC3bi to human E is weak and requires both large amounts of  fixed 
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iC3b and low ionic strength. With phagocytic cells, EC3bi binds to both CRa and 
CRy, so that neither anti-CR~ nor fluid-phase C3b produces much inhibition of 
EC3bi rosette formation (Table III and references 13, 41). Similarly, lymphocytes 
bind iC3b-ms and EC3bi to both CR~ and CR2 (Table II and reference 13). The 
binding of iC3b-ms and EC3bi to monocyte and neutrophil CR1 was demon- 
strated by anti-CRl inhibition of rosettes in EDTA buffers that prevented iC3b 
binding to CR~ (Table II and III). Anti-CR1 also blocked EC3bi rosettes com- 
pletely with human E that lacked CR3 detectable by EC3bi rosette formation. 
EC3bi bearing small amounts of iC3b bound primarily to CRs and not to CRy. 
When these EC3bi were tested in isotonic buffers containing calcium and 
magnesium, monocyte and neutrophil rosette formation was unaffected by anti- 
CR~ but almost completely inhibited by anti-Mac-1 (Table III, reference 21). 
With greater amounts of fixed iC3b, the EC3bi bound to both CRl and CR3, 
and neither anti-CR~ nor anti-Mac-1 produced significant inhibition of rosettes. 
An important recent finding provided additional confirmation of both the ability 
of phagocyte CR~ to bind EC3bi and the identity of CR~ with Mac-1. Two sibling 
patients were discovered who had an apparent genetic deficiency of the leukocyte 
Mac-1 antigen. Monocytes and neutrophils from these patients formed normal 
percentages of EC3bi rosettes in calcium-magnesium buffer, but these EC3bi 
rosettes were inhibited completely by F(ab')2 anti-CR~ (Ross, G. D., R. A. 
Thompson, M. J. Walport, R. H. R. Ward, J. Lida, R. A. Harrison, and P. J. 
Lachmann, manuscript in preparation). 
iC3b had a much lower affinity for CR~ than did either C3b or C4b. Maximum 
levels of  immune adherence in low ionic strength buffer required "~9 times more 
iC3b than C3b (3.5 × 10 4 iC3b per EC3bi vs. 4.0 × 103 C3b per EC3b) and "-3 
times more iC3b than C4b (9.0 x 103 C4b per EAC14b) (29, 30). Because EC3bi 
contained "~5% contaminating C3b, it appeared possible that EC3bi binding to 
CRj might be due entirely to this contaminating C3b. However, this was dis- 
counted because treatment of EC3bi with 10 ~g/ml trypsin, that cleaved fixed 
iC3b to C3d but did not cleave contaminating C3b (Table I) (42), completely 
abolished detectable CRy-dependent rosetting of the resulting EC3d. CRl-de- 
pendent rosetting with C3b (18, 20), C4b (18), and iC3b (Table III) was 
considerably enhanced by low salt buffers, demonstrating that the CRy-binding 
site was partially charge dependent. 
The identification of a low affinity binding site(s) in iC3b for CR1 and H 
supported previous findings that the CRl-binding site was detectable in C3c (13, 
30). In the present study, highly purified C3c was coupled to fluorescent 
microspheres, and the resulting C3c-ms were shown to bind only to CRy. 
Attempts to use C3c-ms to investigate [1251]-H binding to C3c were not successful, 
as a density of oil could not be found that would allow rapid separation by 
centrifugation of the C3c-ms from an aqueous phase containing unbound [125I]- 
H. 
The binding site for CR2 had been previously shown to be present in both 
iC3b and C3d, but not in C3b (4, 13). The C3d,g fragment, that is probably the 
normal bound end product of  C3 degradation (6, 17), had not been previously 
examined for binding to C receptors or other C3 ligands. Both C3d,g-ms (Table 
II) and EC3d,g (Table IV) bound t o  CR2, as rosetting was inhibited by C3d-OR. 
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However, a comparison of EC3d,g and EC3d indicated that CR2 had a higher 
affinity for C3d,g than for C3d (Fig. 2). Although fluid-phase C3d inhibited 
EC3d rosette formation (13), more than 1.0 mg/ml  of C3d was required to 
inhibit EC3d,g rosette formation (data not shown). Because of this finding and 
the demonstration of C3d,g-ms (Table II) and EC3d,g (Table III) binding to 
phagocytic cells, it was at first believed that C3d,g bound to CR3 (43, 44). 
Subsequently however, C3d-OR complexes were found to block C3d,g-ms and 
EC3d,g rosette formation with all cell types, and anti-Mac-1 (anti-CR3) was found 
to have no effect on EC3d,g rosette formation (data not shown). C3d-OR 
resembled C3b-OR (20) in having a much greater ability to block C receptors 
than did uncomplexed C3d or C3b. The most potent inhibitor of CR~ was C3d,g- 
OR. The CR2 on  Raji cells were completely blocked by treatment with microgram 
amounts of C3d,g-OR, and Raji cells were still unable to form EC3d,g or EC3d 
rosettes after three washing steps (Ross, G., unpublished observation). Because 
EC3d,g had a higher affinity for CR~ than did EC3d, the g portion of EC3d,g 
was saturated with monoclonal anti-C3g to determine if this might block the 
CR2-binding site. Because the attachment of an intact IgG molecule to the g 
region (8,000 daltons) caused no detectable inhibition of Raji cell rosette for- 
mation, it appears unlikely that C3g forms a part of  the CRz-binding site. An 
alternative explanation for the higher affinity of CR~ for C3d,g as compared to 
C3d may be the much greater electrophoretic charge of  C3d,g (17). As with CR1 
and CRy, the rosetting activity of CRy-bearing ceils was greatly enhanced in low 
ionic strength buffer (26), indicating that charge interactions were very important 
for the CRy-binding site. Perhaps the charge contributed by the anionic g region 
of C3d,g enhances the attraction of CR2 for the d region of C3d,g. 
The enhanced CR~ binding of C3d,g as compared to C3d probably also 
explains the observed rosette formation of monocytes and neutrophils with 
C3d,g-ms and EC3d,g (Table II and IV). Because phagocytes did not bind C3d- 
ms (13) or EC3d (13, 21), nor stain with anti-CR2 (26), these cells were previously 
believed to lack CR2. EC3d,g binding to phagocytic cells required >5.0 × 10 4 
C3d,g molecules per EC3d,g, and was greatly enhanced by low ionic strength 
buffer. Because EC3d,g contained ,~5% C3b and iC3b detectable with [~sI]- 
anti-C3c (Table I), the involvement of this contaminating C3b and iC3b in 
EC3d,g rosette formation was investigated. Anti-CR~ did produce 18% inhibition 
of  monocyte-EC3d,g rosettes, but C3d-OR produced an average of  72% inhibi- 
tion. In addition, C3d,g-ms binding to phagocytes was inhibited by C3d-OR but 
not by anti-CR~ in EDTA buffers, indicating that C3d,g-ms did not bind to CRI 
or CR3 (Table II). Thus, the data suggest that phagocytic cells may express very 
small amounts of  CR2. In the future, tests for anti-CR2 inhibition of  phagocyte 
EC3d,g rosettes will be required to confirm this conclusion. 
Because iC3b binds to all three types of C3 receptors, it has been particularly 
difficult to define the cell type distribution of CR3. For example, iC3b-dependent 
rosette formation with anti-CR2- or C3d-treated B lymphocytes was thought to 
detect B lymphocyte CR3 (13). With recognition both that B lymphocyte CR~ 
could bind to fixed iC3b and that B cells lacked the Mac-1 antigen (19), it now 
appears likely that B cells lack CR3 and express only CR1 and CR2. On the other 
hand, the cytotoxic activity of antibody-dependent killer cells, that express the 
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Mac-1 antigen (19) and lack CR1 (28), has been shown to be enhanced by target 
cell-bound iC3b (45), probably indicating that this other type of lymphoid cell 
does indeed express CRy. 
A particularly interesting finding was that CR3 had a conglutininlike binding 
activity for fixed iC3b. Previous studies of EC3bi binding to phagocytic cells did 
not detect any significant inhibition by EDTA or NADG, as EC3bi were bound 
to CR1 whenever CR3 were inhibited. Characterization of the CR3-binding site 
thus required prior blockade of neutrophil or monocyte CRl with anti-CRy. 
Comparison of CR3 and K revealed that both ligands required calcium and were 
inhibited by NADG (Table V). However, CR3 differed from K in that a small 
amount of CR3 activity was detected in magnesium/EGTA, and a mixture of 
calcium and magnesium produced significantly more CR3 activity than did 
calcium alone. In addition, CR~ activity was less sensitive to NADG than was K 
activity (Table V). Thus, while both CR3 and K may bind to the same carbohy- 
drate in iC3b, the CR3 requirement for magnesium and greater resistance to 
NADG inhibition suggests that CR3 may bind to a second site in iC3b that does 
not bind to K. 
Additional experiments in the future will be required to confirm the identity 
of a single binding site for H and CRy. It is of interest that a C3-affinity-purified 
antibody was produced that was specific for the idiotype of anti-H antibody and 
blocked the uptake of [3H]-labeled H onto both EC3b and lymphocyte H 
receptors (46). This same anti-anti-H not only bound to EC3b (46), but also 
bound to EC3bi (Lambris, J., unpublished observation), and thus was probably 
specific for the H-binding site of  C3. In the future, attempts will be made to 
produce more of this antibody to ascertain if it blocks simultaneously both the 
H and CR1 binding sites in C3b. The similarity of the CR3 and K binding sites 
also requires further study. K not only binds a carbohydrate in fixed iC3b, but 
also is known to bind directly to certain mannan-containing extracts derived 
from zymosan (42). Because monocytes express mannan-specific receptors (47), 
and neutrophils are able to bind weakly to unopsonized zymosan (48), it will be 
especially important to determine if phagocyte CRs are mannan-specific and able 
to bind yeast particles to phagocytes. Finally, the similarity of CR3 and K suggests 
the possibility that bovine serum K may be a secreted form of leukocyte mem- 
brane CR3. 
S u m m a r y  
The many different recognized functions of C3 are dependent upon the ability 
of the activated C3 molecule both to bind covalently to protein and carbohydrate 
surfaces and to provide binding sites for as many as eleven different proteins. 
The location of  the binding sites for six of these different proteins (factors B and 
H, complement receptors CRy, CR2 and CR.% and conglutinin) was examined in 
the naturally occurring C3-fragments generated by C3 activation (C3b) and 
degradation by Factor I (iC3b, C3c, C3d,g) and trypsin (C3d). Evidence was 
obtained for at least four distinct binding sites in C3 for these six different C3 
ligands. One binding site for B was detectable only in C3b, whereas a second 
binding site for H and CR1 was detectable in both C3b and iC3b. The affinity 
of the binding site for H and CR1 was charge dependent and considerably 
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reduced in iC3b as compared to C3b. H binding to iC3b-coated sheep erythro- 
cytes (EC3bi) was measurable only in low ionic strength buffer (4 mS). The 
finding that C3c-coated microspheres bound to CR1, indicated that this second 
binding site was still intact in the C3c fragment. However, H binding to C3c was 
not examined. A third binding site in C3 for CR2 was exposed in the d region 
by factor I cleavage of C3b into iC3b, and the activity of this site was unaffected 
by the further I cleavage of iC3b into C3d,g. Removal of the 8,000-dalton C3g 
fragment from C3d,g with trypsin forming C3d, resulted in reduced CR2 activity. 
However, because saturating amounts of monoclonal anti-C3g did not block the 
CR2-binding activity of EC3d,g, it appears unlikely that the g region of C3d,g or 
iC3b forms a part of the CR2-binding site. In addition, detergent-solubilized 
EC3d (C3d-OR) inhibited the CR2-binding activity of EC3d,g. Monocytes and 
neutrophils, that had been previously thought to lack CR2 because of their 
inability to form EC3d rosettes, did bind EC3d,g containing >5 × 10 4 C3d,g 
molecules per E. The finding that monocyte and neutrophil rosettes with EC3d,g 
were inhibited by C3d-OR, suggested that these phagocytic cells might indeed 
express very low numbers of CR2, and that these CR2 were  detectable with 
EC3d,g and not with EC3d because C3d,g had a higher affinity for CR2 than did 
C3d. A fourth C3 binding site for CR~ and conglutinin (K) was restricted to the 
iC3b fragment. Because of simultaneous attachment of iC3b to phagocyte CR~ 
and CR3, the characteristics of iC3b binding to CR3 could only be examined with 
phagocytes on which the CR~ had been blocked with anti-CRy. Inhibition studies 
with EDTA and N-acetyI-D-glucosamine demonstrated a requirement for both 
calcium cations and carbohydrate in the binding of EC3bi to CR3 and to K. 
However, CRs differed from K in that magnesium cations were required in 
addition to calcium for maximum CR3 binding activity, and NADG produced 
less inhibition of CR~ activity than of K activity. 
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